Evolution of haemostatic parameters and risk of bleeding during treatment with cefazolin
- 69 Downloads
In 2017, five cases of severe haemorrhages during treatment with cefazolin occurred in France. The aim of this study was to assess the risk of haemorrhage related to treatment with cefazolin by evaluating haemostatic parameters and bleeding events. A retrospective study was conducted from January 2016 to December 2017. Two populations were analysed: (i) overall population, which included all patients treated with cefazolin during this period and (ii) coagulation study population, which included all patients treated with cefazolin with available coagulation parameters (activated partial thromboplastin time (aPTT) and international normalised ratio (INR) at baseline and at the end of treatment or EoT). Values of either aPTT or INR at baseline and at EoT were compared. Cases of severe haemorrhages were reported and correlated with values of aPTT and INR. Overall, 132 patients received cefazolin and 59/132 (45%) were included in the coagulation study group. A significant increase of median aPTT was observed from baseline to EoT (39.5 and 44.3 sec; p = 0.004, respectively). Overall, severe haemorrhage occurred in 7/132 (5%) patients. Coagulation parameters were available in three of them, and no correlation was observed between bleeding events and aPTT increase. This study showed that bleeding is probably more frequent than ever reported before during cefazolin treatment. The significant increase of aPTT observed during cefazolin treatment was not correlated with risk of haemorrhage. Further studies are needed to explore the possible physio-pathological pathways behind the modification of haemostatic parameters and risk of haemorrhage.
KeywordsCefazolin Haemorrhage Activated partial thromboplastin time Coagulation Bleeding International normalised ratio
Compliance with ethical standard
Conflicts of interest
The authors declare that they have no conflict of interest.
For this type of study, formal consent is not required.
Because this study did not require neither further laboratory analysis nor different clinical acts than daily clinical routine, a written consent form was not proposed to any eligible patients.
- 1.Bassetti M, Righi E, Astilean A, Corcione S, Petrolo A, Farina EC, De Rosa FG (2015) Antimicrobial prophylaxis in minor and major surgery. Minerva Anestesiol 81:76–91Google Scholar
- 3.Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdanpanah Y, Andremont A, Duval X, Lescure FX (2018) Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect 24:125–132CrossRefGoogle Scholar
- 4.McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, Jones M, Albertson JP, Nair R, O'Shea AMJ, Schweizer ML (2017) comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis 65:100–106CrossRefGoogle Scholar
- 5.Gay E, Barthel A, Rouzic N, Henriot B, Quélennec B, Lorleac'h A, Prades N, Schmitt F (2017) Cefazolin and coagulation disorders: a case report. Ann Biol Clin (Paris) 76:104–106Google Scholar
- 6.Angles E, Mouton C, Perino J, Remy A, Ouattara A (2017) Hypoprothrombinemia and severe perioperative hemorrhagic complications in cardiac surgery patients treated with high-dose cefazolin for infective endocarditis. Anaesth Crit Care Pain Med. https://doi.org/10.1016/j.accpm.2017.07.006
- 12.Lerner PI, Lubin A (1974) Letter: coagulopathy with cefazolin in uremia. N Engl J Med 290:1324Google Scholar
- 15.http://servvidal:8012/showProduct.html?productId=3348 (last accessed on Thursday, 18 Oct 2018)Google Scholar
- 17.https://sitegpr.com/fr/ (last accessed on Friday, 16 Mar, 2018)
- 19.Hasegawa H, Ohkochi A, Chiba J, Hirai Y, Fukuda E, Iwamura K, Fujii S, Takeo H, Ogata T, Tatsumi K (1988) Study on the effectiveness and safety of cefmenoxime in the treatment of respiratory tract infections. Tendency toward clinical haemorrhage related to the treatment. Jpn J Antibiot 41:1285–1294CrossRefGoogle Scholar
- 20.Agnelli G, Guerciolini R, Boldrini F, Tonzani A, Della Torre P, Nenci GG, Del Favero A (1988) Effects of cefamandole on hemostasis in patients undergoing hip replacement with heparin prophylaxis. Chem Aust 7:396–399Google Scholar
- 21.Kikuchi S, Ando A, Minato K (1991) Acquired coagulopathy caused by administration of parenteral broad-spectrum antibiotics. Rinsho Byori 39:83–90Google Scholar
- 25.Shah MD, Wardlow LC, Stevenson KB, Coe KE, Reed EE (2018) Clinical outcomes with penicillin versus alternative β-lactams in the treatment of penicillin-susceptible Staphylococcus aureus bacteremia. Pharmacotherapy. https://doi.org/10.1002/phar.2124
- 27.Monogue ML, Ortwine JK, Wei W, Eljaaly K, Bhavan KP (2018) Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. J Infect Public HealthGoogle Scholar
- 28.Eljaaly K, Alshehri S, Erstad BL (2018) Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin. Antimicrob Agents Chemother 62Google Scholar
- 30.Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX (2018) CloCeBa study group: Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. BMJ Open 8:e023151CrossRefGoogle Scholar
- 31.Lee BJ, Rao SN, Wang SK, Lee JY, Lakada IY, Gilbert EM, Barr VO, Postelnick MJ, Sutton SH, Zembower TR, Bolon M, Scheetz MH, Rhodes NJ (2017) Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. Int J Antimicrob Agents 49:650–654CrossRefGoogle Scholar
- 38.Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, Jouan-Flahault C, Horellou MH, Leynadier F, Liozon E, Pouchot J, Robin JP, Sanderson F, Schaeffer A, Sicard D, Staikowsky F, Wechsler B, Zittoun R (1998) Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 105:400–408CrossRefGoogle Scholar
- 39.Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J (2017) Effects of oritavancin on coagulation tests in the clinical laboratory. Antimicrob Agents Chemother 61Google Scholar